http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Lineage Cell Therapeutics (LCTX), AgeX Therapeutics (AGE) Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells
-
Lineage Cell Therapeutics and AgeX Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells
-
AgeX Therapeutics and Lineage Cell Therapeutics Announce Issuance of U.S. Patent for Method of Generating Induced Pluripotent Stem Cells
-
Lineage Cell Therapeutics (LCTX) Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program
-
Lineage Cell Therapeutics Provides Update on SCiStar Clinical Study and OPC1 Spinal Cord Injury Program
-
Lineage Cell Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
-
Lineage Cell Therapeutics to Report Third Quarter 2019 Financial Results and Provide Business Update on November 12, 2019
-
Lineage Cell Therapeutics to Host Therapeutic Area Experts at Solebury Trout Investor Event on November 15, 2019
-
Lineage Cell Therapeutics Presents Encouraging Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual Scientific Meeting
-
Lineage Cell Therapeutics to Present at Dawson James Securities 5th Annual Small Cap Growth Conference on October 29, 2019
-
Lineage Cell Therapeutics Presents New OpRegen® Data at American Academy of Ophthalmology Annual Meeting
-
Lineage Cell Therapeutics to Chair Session and Present Data on Vision Restoration Program at Society for Neuroscience’s 49th Annual Scientific Meeting on October 23, 2019
-
Lineage Cell Therapeutics to Present New OpRegen® Data at American Academy of Ophthalmology Annual Meeting on October 14, 2019
-
Lineage Cell Therapeutics to Present at 2019 Cantor Global Healthcare Conference on October 4, 2019
-
Lineage Cell Therapeutics (LCTX) Provides Update on Renevia Commercialization Plans
-
Lineage Cell Therapeutics Provides Update on Renevia® Commercialization Plans
-
Lineage Cell Therapeutics to Present at 2019 Cell & Gene Meeting on the Mesa on October 3, 2019
-
Lineage Cell Therapeutics (LCTX) Receives CE Mark Approval for Renevia
-
Lineage Cell Therapeutics Receives CE Mark Approval for Renevia®
-
Lineage Cell Therapeutics Conducts Sale of Shares in OncoCyte Corporation
-
Lineage Cell Therapeutics to Present at H.C. Wainwright 21st Annual Global Investment Conference on September 9, 2019
-
Lineage Cell Therapeutics (LCTX) Announces Issuance of U.S. Patent for Method of Treating Spinal Cord Injury With Stem Cell-Derived Oligodendrocyte Progenitor Cells
-
Lineage Cell Therapeutics Announces Issuance of U.S. Patent for Method of Treating Spinal Cord Injury With Stem Cell-Derived Oligodendrocyte Progenitor Cells
-
Lineage Cell Therapeutics Announces Data From Vision Restoration Program Published in Stem Cells and Development Journal
-
Lineage Cell Therapeutics Announces Issuance of U.S. Patent for System for Generating Immunogenic Dendritic Cells
-
Lineage Cell Therapeutics to Ring Opening Bell at the New York Stock Exchange on August 21, 2019
-
Lineage Cell Therapeutics Awarded NIH Grant for Innovative Vision Restoration Program
-
Lineage Cell Therapeutics Launches New Corporate Brand

